Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-22 | Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut. Dr. Suzdak’s will contribute his extensive pharmacology and pharmaceutical management experience to the Board of Directors. |
| 2014-04-18 | Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut. Dr. Suzdak’s will contribute his extensive pharmacology, clinical development, business development, and pharmaceutical management experience to the Board of Directors. |
| 2015-04-14 | Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut. Dr. Suzdak contributes his extensive pharmacology, clinical development, business development, and pharmaceutical management experience to the Board of Directors. |
| 2016-04-18 | Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut. Dr. Suzdak contributes his extensive pharmacology, clinical development, business development, and pharmaceutical management experience to the Board of Directors. |
| 2017-02-24 | Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut. Dr. Suzdak contributes his extensive pharmacology, clinical development, business development, and pharmaceutical management experience, including his day-to-day leadership of the Company, to the Board of Directors. |
| 2018-04-23 | Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut. Dr. Suzdak contributes his extensive pharmacology, clinical development, business development, and pharmaceutical management experience, including his day-to-day leadership of the Company, to the Board of Directors. |
| 2018-07-23 | Peter Suzdak Includes Dr. Suzdak’s options to purchase 494,292 shares of Common Stock that are currently exercisable or exercisable within 60 days of July 10, 2018. |
Data sourced from SEC filings. Last updated: 2026-02-03